Outcome of Board Meeting

Date: August 14, 2026 To, To, BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Plot no. C/1, G Block Dalal Street – Fort Bandra Kurla Complex, Bandra (East), Mumbai 400 001 Mumbai - 400 051 Scrip Code: 544578 NSE Symbol: RUBICON ISIN: INE506V01022 Sub: Unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (“SEBI Listing Regulations”), the Board of Directors of the Company at its meeting held today i.e., August 14, 2026, has inter-alia approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026; In this regard, we are enclosing herewith as follows: (a) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026; and (b) Limited Review Report issued by Statutory Auditors of the Company. A QR Code, along with the web-link to the aforesaid Unaudited Standalone and Consolidated Financial Results, will be published in the newspapers in accordance with the SEBI Listing Regulations. The Meeting of the Board of Directors of the Company commenced at 03:00 PM (IST) and concluded at 04.15 PM (IST). The above-mentioned documents will also be available on the Company’s website www.rubicon.co.in under the Investors Section. Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744 Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India �� +91-22-61414000 / 50414000 | ����� reachus@rubicon.co.in | � www.rubicon.co.in Kindly take the above information on record. Thanking you, Yours faithfully, For Rubicon Research Limited (Formerly known as Rubicon Research Private Limited) Deepashree Tanksale Company Secretary M. No. A28132 Encl.: As above Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744 Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India �� +91-22-61414000 / 50414000 | ����� reachus@rubicon.co.in | � www.rubicon.co.in Rubicon Research Limited Regd office: MedOne House, B-75, Road No. 33, Wagle Estate, Thane West- 400 604, Maharashtra, India CIN:L73100MH1999PLC119744 I Website: www.rubicon.co.in Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 (₹ in millions) Quarter ended Year ended Particulars June 30, March 31, June 30, March 31, 2026 2026 2025 2026 (Unaudited) (Unaudited) (Audited) (Audited) Refer note (vii) Income I Revenue from operations 4,277.30 3,898.78 2,780.26 13,060.82 II Other income 24.11 35.81 14.38 108.32 III Total income (I+II) 4,301.41 3,934.59 2,794.64 13,169.14 IV Expenses: a) Cost of materials consumed 1,254.47 1,228.15 1,140.13 4,530.89 b) Changes in inventories of finished goods and work-in-progress 100.12 (67.03) (187.97) (333.58) c) Employee benefits expense 515.21 427.38 371.30 1,642.65 d) Finance costs 60.13 53.96 88.48 309.60 e) Depreciation and amortisation expense 105.68 101.66 82.95 377.48 f) Other expenses 1,159.23 1,248.62 825.39 4,114.31 Total Expenses (IV) 3,194.84 2,992.74 2,320.28 10,641.35 V Profit before tax (III-IV) 1,106.57 941.85 474.36 2,527.79 VI Tax expense i) Current tax 230.52 286.43 1 00.52 681.74 ii) Deferred tax 51.56 (49.80) 2 2.32 (38.14) iii) Tax expense relating to earlier years (net) - 5 .02 - 2.54 Total tax expense (net) (VI) 282.08 241.65 122.84 646.14 VII Net Profit after tax for the period/ year (V-VI) 824.49 700.20 351.52 1,881.65 VIIIOther comprehensive income/(loss) for the period/year a) (i) Items that will not be reclassified to profit or loss 0.70 (0.49) (4.80) (10.69) (ii) Income tax on items that will not be reclassified to profit or loss (0.18) 0.12 1.21 2 .69 Total other comprehensive income/(loss) for the period/year (VIII) 0.52 (0.37) (3.59) (8.00) IX Total comprehensive income for the period/year (VII+ VIII) 825.01 699.83 347.93 1,873.65 X Paid-up equity share capital - face value ₹ 1/- each 165.38 165.09 154.13 165.09 XI Other equity 13,367.64 X Earnings per equity share of ₹ 1/- each (not annualised for the quarter) (a) Basic earnings per share (in ₹) 4.99 4.25 2.28 11.83 (b) Diluted earnings per share (in ₹) 4.94 4.20 2.26 11.67 See accompanying notes to the standalone financial results Research and development revenue expenditure incurred (included above) 596.76 6 08.90 364.76 1,976.98 Rubicon Research Limited Notes: (i) TheaboveunauditedStandalonefinancialresultsofRubiconResearchLimited(the'Company')forthequarterendedJune30,2026,havebeenreviewedbytheAuditCommitteeandapproved by the Board of Directors at their respective meetings held on August 14, 2026. The Statutory Auditors of the Company have carried out Limited Review of the aforesaid results. (ii) TheunauditedStandalonefinancialresultsoftheCompanyhavebeenpreparedinaccordancewiththeIndianAccountingStandards(“IndAS”)prescribedundersection133oftheCompanies Act,2013andareincompliancewithpresentationanddisclosurerequirementsofRegulation33oftheSecuritiesandExchangeBoardofIndia(ListingObligationandDisclosureRequirements) Regulations 2015, as amended (''the Regulations"). (iii) DuringthepreviousyearendedMarch31,2026,theCompanyhadreceivedanamountof₹4,712.74million(netoffestimatedIPOexpenseof₹287.26million)fromproceedsoutoffreshissue of equity shares . The utilization of the net IPO proceeds is summarized as below: Amount to be Unutilised amount Utilised upto June Sr No. Objects of the Issue as per prospectus utilised as per as on June 30, 30, 2026 prospectus 2026 Prepayment or scheduled repayment of all or a portion of certain 1 3,100.00 2,757.00 343.00 outstanding borrowings availed by our Company Funding inorganic growth through unidentified acquisitions and other 2 1,612.74 1,150.05 462.69 strategic initiatives and General corporate purposes Total 4,712.74 3,907.05 805.69 Pursuant to the approval of the Board of Directors of the Company dated May 29, 2026, the timeline for utilisation of the unutilised IPO proceeds has been extended up to March 31, 2027. (iv) TheBoardofDirectorsoftheCompany,atitsmeetingheldonJuly20,2026,approvedtheSchemeofAmalgamationofKiaHealthTechPrivateLimited(“theTransferorCompany”)with RubiconResearchLimited(“theTransfereeCompany”or“theCompany”).TheSchemeofAmalgamationhasbeenfiledwiththeRegistrarofCompanies,NaviMumbaionAugust3,2026, underthefast-trackmergerrouteprovidedunderSection233oftheCompaniesAct,2013,readwiththeapplicablerules,andissubjecttothenecessaryapprovalsandcompliancesunderthe applicable laws. As the Scheme has not yet become effective, no accounting effect of the proposed amalgamation has been given in these financial results for the quarter ended June 30, 2026. (v) The Company is primarily engaged in a single business segment viz "Sale of Pharmaceuticals products". Therefore there are no other reportable segments for the Company as per requirements of Ind AS 108 'Operating Segment'. (vi) DuringthequarterendedJune30,2026,theCompanyhasenteredintodefinitiveagreementtoacquire85%stakeinArinnaLifesciencesLimitedfortotalconsiderationof₹1,759.17million which is completed on April 30, 2026 in accordance with terms agreed under the Share Purchase Agreement. (vii) ThefiguresforthequarterendedMarch31,2026arebalancingfiguresbetweentheauditedfiguresofthefullfinancialyearandthereviewedyear-to-datefiguresuptothethirdquarterofthat financial year. (viii) These financial results are also available on the Company's website (https://www.rubicon.co.in) and on the stock exchange website (www.bseindia.com) and (www.nseindia.com) For and on behalf of Board of Directors of Rubicon Research Limited Parag Sancheti Place: New Jersey, USA Director and Chief E [Showing first 8,000 characters — download PDF for full document]